Spectral MD, a medical technology company, is set to undergo a transformative merger with Rosecliff Acquisition Corp, a move that will reshape the company and lead to its rebranding as Spectral AI. The merger will also facilitate the company’s listing on the NASDAQ under the ticker symbol MD AI instead of its current CLF designation.
Vince Capone, General Counsel of Spectral MD, recently discussed the latest developments at the company in an interview. Capone emphasized the significance of Rosecliff Acquisition Corp filing Form 424, a crucial step in the ongoing journey of Spectral MD. This filing indicates the effectiveness of the RS-4 with Rosecliff and paves the way for a shareholder meeting to approve the transaction.
One of the key milestones highlighted by Capone was the successful clearance of the SEC examiner’s review, a pivotal step for the merger. Notably, the timeline for this process has been accelerated compared to the typical three to four months, showcasing the company’s agile approach.
Looking ahead, Spectral MD aims to achieve further progress by September 8, targeting the NASDAQ listing and exiting other markets. Shareholder meetings for both Spectral MD and Rosecliff are scheduled for August 31 and September 6, respectively, underscoring the rapid pace of developments.
Capone expressed his enthusiasm for the exciting journey ahead and acknowledged the dedicated efforts of the team. The transformation into Spectral AI promises to be a significant stride for the company, and stakeholders eagerly anticipate the upcoming listing and further updates.
With its rebranding and listing on the NASDAQ, Spectral MD aims to position itself as a leading player in the field of medical technology. Through its innovative solutions, Spectral AI aims to revolutionize the healthcare industry by leveraging artificial intelligence and advanced spectral imaging technologies.
The merger with Rosecliff Acquisition Corp will not only provide Spectral MD with the necessary resources and capital but also open doors to new opportunities and partnerships. As Spectral AI, the company aims to further its mission of improving patient outcomes by providing healthcare professionals with cutting-edge AI-powered diagnostic tools.
In summary, Spectral MD’s merger with Rosecliff Acquisition Corp will redefine the company and propel it towards a new phase of growth and innovation as Spectral AI. With the upcoming NASDAQ listing and the promise of advanced AI technologies, Spectral MD is poised to make a significant impact in the medical technology sector. Stakeholders eagerly await the next steps in this exciting journey.
